Results 81 to 90 of about 16,939 (115)

Atorvastatin Induced Erythrocytes Membrane Blebbing

Dose-Response, 2019
Atorvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzymeA reductase, is usually used for the treatment of hypercholesterolemia. Besides its pharmacological and side actions, its toxic effects on human nucleus devoid of erythrocytes are still ...
Rumaisa Bashir Rana, Kashif Jilani, Muhammad Shahid, Muhammad Riaz, Mazhar Hussain Ranjha, Ismat Bibi, Asma Asghar, Muhammad Irfan   +7 more
doaj   +1 more source

Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention

, 2016
Rolf P Kreutz,1,2 Jeffrey A Breall,1 Anjan Sinha,1 Elisabeth von der Lohe,1 Richard J Kovacs,1 David A Flockhart,2,† 1Krannert Institute of Cardiology, 2Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN ...
Breall JA, Sinha A, Flockhart DA, Kovacs RJ, Kreutz RP, von der Lohe E   +5 more
core  

Dose-dependent effects of atorvastatin on myocardial infarction

, 2015
Olga Barbarash, Olga Gruzdeva, Evgenya Uchasova, Ekaterina Belik, Yulia Dyleva, Victoria KaretnikovaFederal State Budgetary Institution, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, the Russian Federation Background ...
Dyleva Y, Uchasova E, Karetnikova V, Belik E, Barbarash O, Gruzdeva O   +5 more
core  

Recurrent Symptomatic Hemorrhage in Cerebral Cavernous Malformations After Discontinuation of Atorvastatin or Placebo

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background A recent randomized prospective controlled trial demonstrated that atorvastatin for up to 2 years was safe but did not significantly alter rebleeding in cerebral cavernous malformations.
Bader Ali, Robert Shenkar, Justine Lee, Roberto J. Alcazar‐Felix, Richard E. Thompson, Agnieszka Stadnik, Georgio Sader, Sean P. Polster, Kelly D. Flemming, James K. Liao, Matthew Sorrentino, Romuald Girard, Daniel F. Hanley, Issam A. Awad   +13 more
doaj   +1 more source

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)

, 2008
The objective of this study was to evaluate the safety and tolerability of atorvastatin 10 mg compared with placebo in 2,838 Patients with type 2 diabetes and no history of coronary heart disease who were enrolled in the Collaborative Atorvastatin ...
Newman, Connie B., Fuller, John H., Durrington, Paul N., Szarek, Michael, Neil, H. Andrew W., Neil, H. Andrew W, Betteridge, D. John, Colhoun, Helen M., Demicco, David A., Auster, Sheila, Hitman, Graham A.   +10 more
core   +1 more source

Toxicity of Atorvastatin on Isolated Brain Mitochondria: Neurotoxicity of Atorvastatin

, 2017
Background: Although the bio kinetics, metabolism and chemical toxicity of Atorvastatin are well known, until recently little attention was paid to the potential neurotoxic effect of Atorvastatin (Atv). Regarding the concrete evidences indicating Atv may
Sanaze Nasohi, Nafiseh Rahmanabadi, Banafsheh Saiid, Jalal Pourahmad, Parvaneh Naserzadeh   +4 more
core   +1 more source

Porównanie intensywnego i standardowego obniżania stężenia lipidów za pomocą atorwastatyny u chorych z dyslipidemią cukrzycową Badanie DALI - podwójnie ślepa, randomizowana próba kliniczna kontrolowana placebo, przeprowadzona u chorych na cukrzycę typu 2 i dyslipidemię cukrzycową [PDF]

, 2002
INTRODUCTION. In patients with type 2 diabetes, intensive glucose regulation, although effective for microangiopathy, has not been shown to have unambiguous preventive effects on the occurrence of cardiovascular disease.
Intervention, Diabetes Atorvastatin Lipid
core  

Outcomes and atorvastatin administration characteristics.

Outcomes and atorvastatin administration characteristics.
Rene Rodríguez-Gutiérrez (17720167), Mariano García-Campa (17720149), Edgar Francisco Carrizales-Sepúlveda (17720158), Neri Álvarez-Villalobos (8441775), Raúl Reyes-Araiza (17720164), José Ramón Azpiri-López (17720170), Ramiro Flores-Ramírez (17720152), Diego Regalado-Ceballos (17720161), Sabrina Rojo-Garza (17720155)   +8 more
core   +1 more source

MP-SDT enhances the therapeutic effect of atorvastatin.

, 2019
(A) Representative images of THP-1-derived foam cells in control, atorvastatin, MP-SDT and atorvastatin combining MP-SDT group detected by Oil Red O staining. Scale bar = 20 μm (B) The percentage of cholesterol efflux in indicated groups.
Zhiguo Zhang (147197), Mingyu Liu (248120), Zhengyu Cao (673219), Hong Jin (65601), Xuezhu Zhao (6817868), Xin Sun (127355), Tianyi Zhang (87298), Ye Tian (220278), Zhaoqian Shen (6817865), Bicheng Li (647182)   +9 more
core   +1 more source

Evaluation of changes in the global longitudinal strain for left ventricular function before and after eight weeks of taking high dose of atorvastatin in patients with coronary slow flow phenomenon

BMC Cardiovascular Disorders
Background Coronary Slow Flow Phenomenon (CSFP) is a well-recognized clinical entity characterized by delayed opacification of coronary arteries in the presence of a normal coronary angiogram.
Nakisa Khansari, Amir Mohammad Salehi, Niloofar Mohammadi, Amir Hossein Yazdi, Zahra Sanaei   +4 more
doaj   +1 more source